Clinical meaning
Off-label prescribing refers to the use of an FDA-approved medication for an indication, population, dosage, route of administration, or duration that is not included in the drug's approved labeling. The FDA approval process evaluates drugs for specific indications through a phased clinical trial system: Phase I (safety and pharmacokinetics in healthy volunteers), Phase II (efficacy and dosing in small patient groups), and Phase III (large randomized controlled trials confirming efficacy and monitoring adverse effects). FDA approval represents the minimum evidence threshold for marketing a drug for a specific indication, but it does not restrict licensed prescribers from using the drug for other evidence-supported purposes. Approximately 20% of all prescriptions in the United States are written for off-label indications, and in certain populations — particularly pediatrics, oncology, and psychiatry — the rate exceeds 50-80% because manufacturers often lack financial incentive to pursue additional FDA indications through costly clinical trials. The pharmacological rationale for off-label prescribing rests on understanding that a drug's mechanism of action often has therapeutic implications beyond the initially studied indication: gabapentin's calcium channel modulation (approved for seizures) provides neuropathic pain relief; amitriptyline's serotonin and norepinephrine reuptake inhibition plus sodium channel blockade (approved for depression) treats chronic pain, migraine prophylaxis, and insomnia; metformin's AMPK activation and reduction of hepatic gluconeogenesis (approved for type 2 diabetes) shows benefit in polycystic ovary syndrome by improving insulin sensitivity and reducing androgen levels; propranolol's beta-adrenergic blockade (approved for hypertension) treats infantile hemangiomas, performance anxiety, essential tremor, and migraine prophylaxis. The evidence hierarchy supporting off-label prescribing ranges from the strongest level (systematic reviews, meta-analyses, and large RCTs) through moderate evidence (cohort studies, case-control studies, pharmacoepidemiologic database analyses) to the weakest support (case series, case reports, expert opinion, and pharmacologic rationale alone). The prescriber's legal and professional liability for off-label use is governed by the standard of care rather than FDA labeling: prescribing is defensible when supported by peer-reviewed literature, national guidelines, or compendia recognized by CMS (such as DRUGDEX, AHFS Drug Information, NCCN Drug & Biologics Compendium), and when the prescriber documents the clinical rationale, discusses the off-label nature with the patient including risks and alternatives, and obtains informed consent. Conversely, prescribing off-label without adequate evidence, failing to monitor for known off-label adverse effects, or neglecting informed consent exposes the prescriber to malpractice liability. In pediatric practice, off-label prescribing is often unavoidable because fewer than 50% of medications used in children have been formally studied in pediatric populations, leading to age-extrapolated dosing using allometric scaling (weight-based or body-surface-area-based adjustments) and careful monitoring given developmental differences in hepatic enzyme maturation, renal function, body composition, and receptor sensitivity.